Literature DB >> 7617840

Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement--patterns of failure.

N A Mayr1, B C Wen, J A Benda, J I Sorosky, C S Davis, R W Fuller, D H Hussey.   

Abstract

PURPOSE: To evaluate involvement of the lower uterine segment (LUS) in adenocarcinoma of the endometrium and to identify patterns of treatment failure.
MATERIALS AND METHODS: Two hundred four patients, aged 29-92 years, with endometrial carcinoma underwent surgery. Postoperative radiation therapy was administered for adverse histologic criteria, including deep myometrial invasion, high grade, or LUS involvement.
RESULTS: The incidence of tumor involvement of the LUS was 19%; of the cervix, 14%; and of the corpus, 67%. Distant metastasis occurred in 3% of patients with LUS involvement and in 17% of patients with cervical involvement. The local recurrence rate was 50% among patients with LUS involvement with no other risk factors and no postoperative radiation therapy and was 3% among those who underwent radiation therapy (P = .023).
CONCLUSION: Early local-regional spread may be the primary mechanism of treatment failure in tumor invasion of the LUS. Aggressive local management, including postoperative radiation therapy, may be necessary.

Entities:  

Mesh:

Year:  1995        PMID: 7617840     DOI: 10.1148/radiology.196.2.7617840

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer.

Authors:  Ryan M Tierney; Matthew A Powell; David G Mutch; Randall K Gibb; Janet S Rader; Perry W Grigsby
Journal:  Radiat Med       Date:  2007-11-26

2.  Incidence of radiation toxicity in cervical cancer and endometrial cancer patients treated with radiotherapy alone versus adjuvant radiotherapy.

Authors:  Andrzej Roszak; Zaneta Wareńczak-Florczak; Krystyna Bratos; Piotr Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2012-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.